Clinical trials: HCMV
Brain Cancer Metastatic, CMV Viremia
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (CMV) therapy and standard-of-care (SOC) in patients with anti-human…
- Trial name
- NCT07383649
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Methodist Hospital Research Institute
HCMV Infection, Hypertension
The Link Between Human Cytomegalovirus (HCMV) and Hypertension
It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity to the animal CMV counterparts, and it…
- Trial name
- NCT01113359
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Chao Yang Hospital
Cytomegalovirus Retinitis, Acute Renal Failure
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
Cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against herpesviruses. Its potency in inhibiting HCMV has been shown in conventional in vitro studies.
- Trial name
- NCT01866397
- Testing
- Cidofovir pharmacokinetics
- Where
- Austria
- Volunteers
- 1 people
- Sponsor
- Medical University of Vienna
Tuberculosis
A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults
This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and immune responses of the investigational HCMV-TB vaccine candidate VIR-1778 in adults in overall good health without HIV…
- Trial name
- NCT07818824
- Testing
- VIR-1778 (5 × 10^5 ffu), VIR-1778 (5 × 10^6 ffu)
- Where
- 2 sites in Peru
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infection, Cytomegalovirus Disease
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult Japanese kidney transplant recipients.
- Trial name
- NCT04129398
- Testing
- Letermovir tablet, Letermovir IV
- Where
- 4 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Hearing Loss, Mental Retardation
Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
The aim of this study is to investigate short and long term consequences from early postnatal HCMV infection transmitted via human milk in very preterm infants (birth weight < 1500 g or gestational age < 32 weeks).
- Conditions
- Hearing Loss, Mental Retardation, Microcephaly, Chorioretinitis
- Trial name
- NCT01151462
- Where
- Norway
- Sponsor
- Oslo University Hospital
Materno-fetal Transfer of Anti-HCMV-IgG, Materno-fetal Transfer of Anti-VZV-IgG
Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns
The aim of the study is to determine the total concentration of HCMV- and VZV-specific IgG-antibodies and the total concentration of neutralizing antibodies against HCMV in neonatal bloodstream depending on gestational age at…
- Trial name
- MoChi-HCMV (NCT02689700)
- Testing
- Blood samples
- Where
- Germany
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital
Cytomegalovirus Infections
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
This study will evaluate the safety, tolerability, and immunogenicity of various doses, formulations, and routes of administration of Human Cytomegalovirus (HCMV) vaccine V160 administered in a 3-dose regimen in healthy adults.
- Trial name
- NCT01986010
- Testing
- V160 Low Dose IM, V160 Medium Dose IM, V160 High Dose IM
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
CMV Disease
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients.
- Trial name
- NCT03443869
- Testing
- Letermovir, Valganciclovir, Acyclovir (ACV)
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 601 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV I Infection
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
- Trial name
- NCT05854381
- Testing
- VIR-1388
- Where
- 10 sites in United States, South Africa
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus
Detection of Human Cytomegalovirus in the Saliva
Direct DNA amplification, viral isolation and specific antibody measurement in saliva 1. From children in day care centers (samples collection will take place during a single week) 2.
- Trial name
- FcrèchMV (NCT00815802)
- Where
- France
- Volunteers
- 655 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Migraine
The Link Between Human Cytomegalovirus Gene Expression and Glutamate Level in Migraine;Relation to Vitamin D Deficiency
1. To correlate serum 25(OH)-vitamin D level with duration, frequency, and severity of migraine headache attacks 2. To evaluate the relationship between the serum level of vitamin D and other indices in patients with migraine. 3.
- Trial name
- NCT06304948
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Assiut University
Human Cytomegalovirus (HCMV)
Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.
Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response.
- Trial name
- NCT07477925
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Lung Transplant, CMV
Letermovir for CMV Prevention After Lung Transplantation
This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with…
- Trial name
- NCT05041426
- Testing
- Letermovir, Valganciclovir
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fernanda P Silveira, MD, MS
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV
This study is to test an experimental HIV Vaccine. About 12 participants, aged 18-55 years and who already have cytomegalovirus (CMV) will take part in this study.
- Trial name
- NCT07801456
- Testing
- VIR-1388
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nonneoplastic Condition
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in…
- Trial name
- NCT00722839
- Testing
- PADRE-CMV fusion peptide vaccine, tetanus-CMV fusion peptide vaccine, agatolimod sodium
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
The objectives of this first-in-human is to evaluate the safety and the immunogenicity of three administrations of a bivalent vaccine candidate against human cytomegalovirus, at three different dose levels.
- Trial name
- NCT02798692
- Testing
- Low dose HB-101, Medium dose HB-101, High dose HB-101
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hookipa Biotech GmbH
Cytomegalovirus (CMV) Infection
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients.
- Trial name
- NCT07009548
- Testing
- Cytogam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fernanda P Silveira, MD, MS
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy
Human cytomegalovirus (HCMV) is the leading infectious agent causing congenital disabilities such as mental retardation, psychomotor delay, hearing loss, speech and language disabilities, behavioural disorders and visual…
- Trial name
- CHILd (NCT03973359)
- Testing
- Hygienic recommendations
- Where
- 12 sites in Italy
- Volunteers
- 23,500 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cytomegalovirus Infections
Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients
Human cytomegalovirus (HCMV) has remained a major cause of morbidity and mortality following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT).
- Trial name
- NCT00284687
- Testing
- Artesunate
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization